We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves New Indication for Antibiotic Vibativ
FDA Approves New Indication for Antibiotic Vibativ
June 28, 2013
The FDA has granted a new indication for Theravance’s antibiotic Vibativ to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) when other treatments fail.